Company Profile
Arcus Biosciences Stock Price, News & Analysis
- Ticker:
- RCUS
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
28.33 USD (+2.27%)
Close
Last updated: August 6, 2026
3.08B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, RCUS closed up 2.27% at $28.33. No new same-company headline was identified in the current news window.
Company overview
Business overview
Arcus Biosciences is an oncology company focused on immuno-oncology combinations and targeted cancer therapies. Its platform is built to create differentiated regimens in solid tumors.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Arcus sits in clinical-stage oncology biotechnology.
Business Model Characteristics
The company depends on clinical data, partnership economics, and the ability to translate combination science into durable cancer programs.
Position Within the Biotechnology Landscape
Arcus is a catalyst-sensitive oncology name whose stock moves on readouts, combination strategy, and partner progress.
Future catalysts
Arcus's catalysts are domvanalimab/zimberelimab combinations and casdatifan in oncology, where the next readouts determine whether the platform can keep its premium. The company remains a key immuno-oncology and HIF-2α story.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Arcus Biosciences (RCUS)?
Arcus Biosciences (RCUS) most recently closed at 28.33 USD, a +2.27% move versus the previous session.
What is the market cap of Arcus Biosciences (RCUS)?
Arcus Biosciences currently has a market capitalization of 3.08B USD on BioPharmSignal.
What does Arcus Biosciences do?
Arcus Biosciences is an oncology company focused on immuno-oncology combinations and targeted cancer therapies. Its platform is built to create differentiated regimens in solid tumors.
On which exchange is RCUS stock listed?
Arcus Biosciences (RCUS) is associated with NYSE, United States, Biopharma.
What is HIF-2?
The company remains a key immuno-oncology and HIF-2α story.
Which conditions is Arcus Biosciences targeting with HIF-2?
Arcus Biosciences is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Arcus Biosciences describe recent progress with HIF-2?
The company remains a key immuno-oncology and HIF-2α story.
What is domvanalimab?
Arcus's catalysts are domvanalimab/zimberelimab combinations and casdatifan in oncology, where the next readouts determine whether the platform can keep its premium.